Press releases
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
- Innate Pharma Reports Full Year 2023 Financial Results and Business Update
More ▼
Key statistics
On Wednesday, Innate Pharma SA (IDDA:FRA) closed at 2.58, -16.77% below its 52-week high of 3.10, set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.58 |
Low | 2.22 |
Bid | 2.68 |
Offer | 2.80 |
Previous close | 2.58 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.86m |
Free float | 62.11m |
P/E (TTM) | -- |
Market cap | 224.26m USD |
EPS (TTM) | -0.1019 USD |
Data delayed at least 15 minutes, as of May 22 2024 14:29 BST.
More ▼